Key result
Higher HbA1c linked to ~15% greater mortality per SD, following a U-shaped risk curve.
Why the study?
The precise impact of HbA1c itself on all-cause mortality, beyond the control of other cardiovascular risk factors, remains uncertain.
Do HbA1c levels associate with long-term mortality in patients undergoing percutaneous coronary intervention?
Cohort (n=4,700)
No
Do HbA1c levels associate with long-term mortality in patients undergoing percutaneous coronary intervention?
Hazard Ratio: 1.15 (95% CI 1.06–1.25)
p-value: p=<0.001
In patients undergoing percutaneous coronary intervention, HbA1c levels exhibit a U-shaped association with long-term all-cause mortality, with the lowest risk observed at levels between 5.3% and 5.9%.
No takes yet. Share an insight, caveat, or question.
Higher HbA1c associated with post-angiography mortality; hypothesis-generating and should not yet change practice.
Dykun et al. (2022) conducted a cohort in coronary artery disease undergoing percutaneous coronary intervention (n=4,700). Hemoglobin A1c (HbA1c) vs. HbA1c >5.3-5.6% was evaluated on all-cause mortality (HR 1.15, 95% CI 1.06-1.25, p=<0.001). Higher HbA1c levels were independently associated with all-cause mortality (HR 1.15 per 1 SD increase; 95% CI 1.06-1.25; p<0.001), with a U-shaped relationship showing best prognosis at 5.3-5.9%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: